Margin.
Pace.
Position.
The whole GTM playbook is being rewritten in real time, across every commercial team at once.
This briefing tells you how the GTM playbook gets rewritten in pharma sales as AI compresses every commercial team. Read it before your competitors hit their first AI-native quarter.
The 10-page briefing. Worth 20 minutes.
One email. One PDF. Worth twenty minutes of your week.
We send it once. Work emails only.
Every commercial director at a Nordic pharma affiliate has had the same Monday. The month-six uptake curve just printed, running fifteen percent below plan. Your market access director is in Stockholm fighting a regional committee leaning toward the competitor's managed-entry agreement. Your best MSL mentioned retirement at the advisory board dinner on Thursday.
You have done this job for twelve years. The pattern used to be simple. Hire reps who knew the therapy area. Run disciplined call cycles. Build KOL relationships through MSL coverage at every major congress. Launch moves to peak over eighteen to twenty-four months and the patent clock does the rest. Something changed.
This is not a you problem. It is an industry problem and a function problem, happening at the same time. Most commercial directors are treating them as two. The ones who see them as one are going to own the next patent cycle of specialty launches.
Same twelve months. Opposite outcomes. The difference is the operator, not the AI.
Your CEO is already asking you about this, and global HQ is about to land a standardised playbook. The briefing below is what you want in your hand before either conversation.
Uptake. Formulary. Retirement.
Three questions every pharma commercial director is tracking. None of them used to be the same question. They are now.
Why is our launch running below peak projection?
Month six on your active launch is below plan and the gap is widening. Your reps are making the call volume. Your MSLs are covering the KOLs. Your access team landed the early formulary wins. The curve still runs behind. Physicians arrive to every meeting having done their own AI-augmented research. Your team shows up with last quarter's preparation.
Why are we losing regional decisions to firms we beat on science?
Your health-economics file is as strong as theirs. Your clinical data is better. The committee still went for the competitor. They did not win on price. They won because their managed-entry proposal addressed the committee's actual concern, and your filing addressed the concern from two years ago. The intelligence flow from the field into the dossier is too slow.
What happens when our best MSLs retire?
Your top three MSLs hold the relationships with the KOLs who chair the guideline committees. Twenty years of scientific trust built call by call, congress by congress. Two of the three are over 55. Once they leave, replacements arrive with good CVs and no relationships. The KOL file has never been transferable. It is now, if you move before the advisory board calendar for next year closes.
What you get when you download
An 11-page report for commercial directors at European mid-market pharmaceutical affiliates. Designed to be read in one sitting before your next leadership team meeting.
Your industry, your function, and why they are one problem
What is happening in pharma commercialisation as a sector. What is happening on your launch floor across field sales, MSLs, and market access right now. And the intersection most commercial directors have not named yet. Plain language you can use with your CEO and global HQ.
Four moves across field, MSLs, market access, and knowledge
How to get your reps into the meeting prepared at the physician's level. How to double MSL effective capacity before the scientific-exchange asymmetry widens. How to double dossier velocity without adding headcount. How to capture what your best MSLs know before they leave, and compound it into the next launch.
Five questions for your next leadership team meeting
Last three formulary decisions that went the other way. Current launch's month-six uptake against plan. Top-three MSL retirement handover. Where the average rep and MSL spend Monday morning. The people already doing what the rest of the affiliate will need to do by 2027. Ask these honestly.
Calibrated for each seat at the table.